Allosteric Modulators for α7 nAChR Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia lack effective solutions for modulating α7 nAChR, particularly in maintaining neurotransmission integrity and selectivity, and have side effects such as dyskinesia and inflammation.
Innovation Solution
Development of a new class of α7 nAChR positive allosteric modulators (PAMs) that enhance the potency of endogenous agonists without disrupting neurotransmission, including specific compounds and pharmaceutical compositions for treating cognitive impairments and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cognitive impairments are used, then therapeutic effects are achieved, but side effects such as dyskinesia and inflammation occur
Solution Approach 1:
The patent changes the pharmacological parameter from direct agonist activity to positive allosteric modulation, fundamentally altering how the drug interacts with the α7 nAChR receptor. This parameter change allows therapeutic effect while eliminating the harmful side effects associated with traditional agonists
Solution Approach 2:
The positive allosteric modulator acts as an intermediary that enhances the effect of endogenous agonists without directly activating the receptor itself. This intermediary approach provides therapeutic benefit while avoiding the direct activation-induced side effects
2Reliability
If α7 nAChR agonists are used to improve cognition, then cognitive function is enhanced, but selectivity and neurotransmission integrity are compromised
Solution Approach 1:
The positive allosteric modulator provides localized enhancement at the α7 nAChR receptor site, selectively amplifying endogenous agonist effects only at this specific receptor without affecting other neurotransmission pathways, thereby maintaining overall system integrity while achieving cognitive enhancement
Data Source
AI summary
The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation